Latest Period
Q2 2026
Security Snapshot
CNS Pharmaceuticals, Inc. - Common Stock (CNSP) Institutional Ownership
CUSIP: 18978H508
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
11
Shares (Excl. Options)
280,434
Price
$4.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CNSP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 280,434
- Total 13F value
- $1,340,474
- Portfolio coverage rank
- 0%
- Share change
- +134,838
- Value change
- +$699,729
- Number of holders
- 11
- Shares outstanding
- 1,487,778
- SEC-reported price per share
- $5.04
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CNSP - CNS Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 18978H508.
- 11 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 11 to 11 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $348,663 to $1,340,474.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 11 institutions filings for Q2 2026.
Security key
18978H508
Latest holder period
Q2 2026
13F holders
11
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
CNSP full holder history
CNS Pharmaceuticals, Inc. SEC filings
CNS Pharmaceuticals, Inc. company facts
CNS Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 18978H508:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
CNSP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 9.9% | +25% | $402,671 | +$279,627 | 159,790 | +227% | Stonepine Capital Management, LLC | 31 Mar 2026 |
| Ikarian Capital, LLC | 9.9% | +70% | $749,706 | +$516,431 | 147,290 | +221% | Ikarian Capital, LLC | 30 Jun 2026 |
As of 30 Jun 2026, 11 institutional investors reported holding 280,434 shares of CNS Pharmaceuticals, Inc. - Common Stock (CNSP). This represents 19% of the company’s total 1,487,778 outstanding shares.
13F concentration
Top 15 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
19%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 9.1% | 135,830 | +196% | 0.11% | $649,267 |
| ADAR1 Capital Management, LLC | 4.7% | 70,000 | 0.02% | $334,600 | |
| Stonepine Capital Management, LLC | 2.8% | 41,573 | -32% | 0.15% | $198,719 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.91% | 13,524 | 0% | 0% | $64,645 |
| VANGUARD FIDUCIARY TRUST CO | 0.69% | 10,226 | 0% | $48,880 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.47% | 6,993 | 0% | $33,427 | |
| UBS Group AG | 0.1% | 1,461 | +100% | 0% | $6,983 |
| Tower Research Capital LLC (TRC) | 0.05% | 799 | -39% | 0% | $3,819 |
| BARCLAYS PLC | 0% | 19 | 0% | $91 | |
| BARRETT & COMPANY, INC. | 0% | 8 | 0% | 0% | $38 |
| DANSKE BANK A/S | 0% | 1 | 0% | 0% | $5 |
| GEODE CAPITAL MANAGEMENT, LLC | 0% | 0 | -100% | $0 | |
| MAI Capital Management | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 | |
| Caitong International Asset Management Co., Ltd | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5